Compare WEN & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEN | ANAB |
|---|---|---|
| Founded | 1969 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2000 | 2015 |
| Metric | WEN | ANAB |
|---|---|---|
| Price | $7.88 | $59.54 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 22 | 12 |
| Target Price | $8.84 | ★ $71.67 |
| AVG Volume (30 Days) | ★ 11.8M | 557.3K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | ★ 8.28% | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $2,176,891,000.00 | $234,603,000.00 |
| Revenue This Year | $2.26 | N/A |
| Revenue Next Year | $0.94 | $52.14 |
| P/E Ratio | $64.92 | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $6.37 | $17.11 |
| 52 Week High | $12.51 | $73.30 |
| Indicator | WEN | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 57.99 | 44.72 |
| Support Level | $7.84 | $53.46 |
| Resistance Level | $8.54 | $67.69 |
| Average True Range (ATR) | 0.38 | 4.31 |
| MACD | 0.05 | -0.81 |
| Stochastic Oscillator | 72.95 | 19.47 |
The Wendy's Co is engaged in operating, developing, and franchising a system of distinctive quick-service restaurants serving high-quality food. The company operates through Wendy's U.S., Wendy's International, and Global Real Estate & Development. Wendy's U.S. and Wendy's International include the operation and franchising of restaurants and derive revenues from sales at company-operated restaurants, as well as royalties, franchise fees, and advertising fund collections from franchised restaurants. Global Real Estate & Development includes real estate activities for owned and leased sites that are leased or subleased to franchisees and includes the company's share of income from its Canadian restaurant real estate joint venture.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).